GR
Gregory W. Roloff, MD
University of Chicago, Loyola University Medical Center, University at Buffalo School of Medicine and Biomedical Sciences
Research areas: Medicine · Hematology · Acute Myeloid Leukemia Research · Acute Lymphoblastic Leukemia research · CAR-T cell therapy research
0000-0003-2109-5152
About
Fellow, Hematology/Oncology
The University of Chicago
Employment
- 2021 - Present
-
Loyola University Medical Center Resident2018 - 2021
Education
-
University at Buffalo School of Medicine and Biomedical Sciences M.D.2013 - 2018
Projects & Funding
Projects & funding information is unavailable.
Publications (25)
- Allogeneic Hematopoietic Cell Transplant Following Standard of Care Brexucabtagene Autoleucel in Adults with B-Cell Acute Lymphoblastic Leukemia: Results from the Real-World Outcomes Collaborative of Chimeric Antigen Receptor T in Adult Acute Lymphoblast… Save
- Improved outcomes with TKI maintenance after brexucabtagene autoleucel in Philadelphia chromosome ALL Save
- Consensus recommendations for CAR T-cell administration in adult acute lymphoblastic leukemia: a modified Delphi study Save
- Real-world toxicity of brexucabtagene autoleucel in adults with relapsed/refractory B-cell acute lymphoblastic leukemia Save
- Outcomes of brexucabtagene autoleucel in patients with relapsed/refractory acute lymphoblastic leukemia with CNS involvement Save
- Real-world outcomes for young adult patients receiving CD19 CAR T-cell therapy Save
- Impact of prior inotuzumab ozogamicin treatment on brexucabtagene autoleucel outcomes in adults with B-cell ALL Save
- Stagnation in quality of next‐generation sequencing assays for the diagnosis of hereditary hematopoietic malignancies Save
- Clinical guideline variability in the diagnosis and care of people at risk for hereditary hematopoietic malignancy syndromes Save
- Allogeneic hematopoietic stem cell transplant outcomes in adults with inherited myeloid malignancies Save
- Clinical and molecular response of AML harboring non-canonical FLT3 N676K driver mutations to contemporary FLT3 inhibitors Save
- Stagnation in quality of next-generation sequencing assays for the diagnosis of hereditary hematopoietic malignancies Save
- Targeted Therapies for the Evolving Molecular Landscape of Acute Myeloid Leukemia Save
- Inherited Susceptibility to Hematopoietic Malignancies in the Era of Precision Oncology Save
- Assessment of technical heterogeneity among diagnostic tests to detect germline risk variants for hematopoietic malignancies. Save
- Next-Generation Sequencing Delineates Clonal Origins and Informs Therapeutic Strategies in Acute Lymphoblastic Leukemia and Histiocytic Sarcoma Save
- Targeted RNA-sequencing for the quantification of measurable residual disease in acute myeloid leukemia. Save
- Molecular Measurable Residual Disease Testing of Blood During AML Cytotoxic Therapy for Early Prediction of Clinical Response. Save
- When to obtain genomic data in acute myeloid leukemia (AML) and which mutations matter. Save
- NY-ESO-1 Vaccination in Combination with Decitabine Induces Antigen-Specific T-lymphocyte Responses in Patients with Myelodysplastic Syndrome Save